Vegf Angiogenesis Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The VEGF (Vascular Endothelial Growth Factor) signaling pathway is a critical regulator of angiogenesis and vascular permeability. Emerging research reveals its central role in neurodegenerative diseases through effects on blood-brain barrier integrity, neurovascular coupling, and direct neuroprotective signaling.
The VEGF family of growth factors and their receptors regulate the formation and maintenance of blood vessels throughout the body, including the specialized vasculature of the brain. In neurodegeneration, VEGF signaling dysfunction contributes to blood-brain barrier breakdown, impaired cerebral blood flow, and loss of neurovascular unit function.
flowchart TD
A[Hypoxia<br/>Ischemia] --> B[HIF-1α<br/>Stabilization] -->
B --> C[VEGF-A<br/>Transcription] -->
C --> D[VEGF-A<br/>Secretion] -->
D --> E[VEGFR2<br/>Dimerization] -->
E --> F{Downstream<br/>Signaling}
F --> G[PI3K/Akt<br/>Pathway] -->
F --> H[PLCγ/DAG/IP3<br/>Pathway] -->
F --> I[MAPK/ERK<br/>Pathway] -->
G --> J[eNOS<br/>Activation] -->
H --> K[Ca2+<br/>Signaling] -->
I --> L[Endothelial<br/>Cell Proliferation] -->
J --> M[Vascular<br/>Permeability] -->
K --> L
L --> N[Angiogenesis)
N --> O[Tip Cells<br/>Stalk Cells] -->
O --> P[Vessel<br/>Sprouting] -->
P --> Q[Pericyte<br/>Recruitment] -->
Q --> R[PDGF-B<br/>PDGFR-β] -->
R --> S[Vessel<br/>Maturation] -->
S --> T[Ang-1/Tie2<br/>Signaling]
| Molecule |
Symbol |
Function |
Disease Relevance |
| VEGF-A |
VEGFA |
Primary angiogenic factor |
AD, PD, ALS |
| VEGF-B |
VEGFB |
Vascular maintenance |
Neuroprotection |
| VEGF-C |
VEGFC |
Lymphangiogenesis |
BBB regulation |
| PlGF |
PGF |
VEGF family member |
Placental growth |
| VEGFR1 |
FLT1 |
VEGF receptor (high affinity) |
Decoy receptor |
| VEGFR2 |
KDR/FLK1 |
Primary signaling receptor |
Angiogenesis |
| VEGFR3 |
FLT4 |
Lymphatic receptor |
Brain borders |
| NRP1 |
NRP1 |
VEGF co-receptor |
Axon guidance |
| NRP2 |
NRP2 |
VEGF co-receptor |
Semaphorin binding |
| PI3K |
PI3K |
Kinase, survival signaling |
Cell survival |
| Akt |
AKT |
Serine/threonine kinase |
eNOS activation |
| eNOS |
NOS3 |
Nitric oxide synthesis |
Vasodilation |
| PLCγ |
PLCG1 |
Phospholipase C |
Calcium signaling |
| MAPK/ERK |
MAPK1/3 |
Cell proliferation |
Endothelial growth |
| Ang-1 |
ANGPT1 |
Angiopoietin-1 |
Vessel stability |
| Ang-2 |
ANGPT2 |
Angiopoietin-2 |
Vessel destabilization |
| Tie2 |
TEK |
Angiopoietin receptor |
Maturation signal |
| PDGF-B |
PDGFB |
Platelet-derived growth factor |
Pericyte recruitment |
| PDGFR-β |
PDGFRB |
PDGF receptor |
Pericyte function |
| HIF-1α |
HIF1A |
Hypoxia response factor |
VEGF transcription |
Under hypoxic conditions, HIF-1α (Hypoxia-Inducible Factor-1α) is stabilized and translocates to the nucleus, where it binds to hypoxia response elements (HREs) in the VEGF gene promoter, driving transcription.
Key triggers in neurodegeneration:
- Chronic cerebral hypoperfusion
- Microvascular rarefaction
- Ischemic events
- Mitochondrial dysfunction
VEGF-A primarily signals through VEGFR2 (KDR/Flk-1), which dimerizes and autophosphorylates upon ligand binding, activating multiple downstream pathways:
- PI3K/Akt pathway: Promotes endothelial cell survival and NO-mediated vasodilation
- PLCγ pathway: Increases intracellular calcium, promotes endothelial proliferation
- MAPK/ERK pathway: Drives endothelial cell proliferation and differentiation
flowchart LR
subgraph Angiogenesis Process
VA[VEGF-A<br/>Activation] --> TS[Tip Cell<br/>Selection] -->
TS --> SM[Stalk Cell<br/>Proliferation] -->
SM --> BS[Branch<br/>Formation] -->
BS --> PS[Pericyte<br/>Recruitment] -->
PS --> VM[Vessel<br/>Maturation] -->
VM --> SC[Stable<br/>Capillary]
end
subgraph Pericyte Recruitment
PDGF[PDGF-B<br/>Release] --> PR[PDGFR-β<br/>Activation] -->
PR --> PM[Pericyte<br/>Migration] -->
PM --> PA[Pericyte<br/>Coverage]
end
The neurovascular unit (NVU) is a complex structural and functional entity comprising endothelial cells, pericytes, astrocytes, neurons, and supporting extracellular matrix. VEGF signaling is central to maintaining NVU integrity.
Components of the NVU:
- Endothelial cells: Form the blood vessel lining, connected by tight junctions
- Pericytes: Embedded in the basement membrane, regulate capillary diameter and blood flow
- Astrocytes: Extend end-feet that ensheath vessels, regulate BBB function
- Neurons: Require constant blood supply, regulate local blood flow through neurovascular coupling
- Smooth muscle cells: Present in larger vessels, control vessel tone
VEGF's role in the NVU:
- Maintains endothelial tight junction integrity
- Supports pericyte survival and function
- Promotes astrocyte polarization
- Enables neurovascular coupling response
- Regulates cerebral blood flow autoregulation
VEGFR1 (Flt-1):
- High affinity for VEGF-A, VEGF-B, and PlGF
- Functions primarily as a decoy receptor
- Regulates vascular patterning during development
- Involved in monocyte migration and inflammation
VEGFR2 (KDR/Flk-1):
- Primary mediator of angiogenic signaling
- Tyrosine kinase activity drives endothelial proliferation
- Responsible for vascular permeability
- Critical for new blood vessel formation
VEGFR3 (Flt-4):
- Primarily regulates lymphatic vessels
- Expressed in brain border regions
- May have roles in CNS fluid drainage
- Ligands: VEGF-C, VEGF-D
VEGF-A exists in multiple isoforms due to alternative splicing:
- VEGF121: Freely diffusible, weak heparin binding
- VEGF165: Balanced heparin binding, most common isoform
- VEGF189: Strong heparin binding, cell-associated
- VEGF206: Rare, highly cell-associated
These isoforms determine VEGF's distribution and signaling kinetics in tissue.
In AD, VEGF signaling is profoundly dysregulated with both beneficial and detrimental effects:
VEGF in Aβ clearance:
- VEGF-A enhances Aβ transport across the BBB via receptor-mediated transcytosis
- Impaired VEGF signaling reduces Aβ clearance
- VEGF receptor expression altered in AD brain
Neurovascular unit dysfunction:
- Capillary rarefaction in AD brain reduces cerebral blood flow
- Endothelial dysfunction impairs autoregulation
- BBB breakdown allows peripheral protein entry
Cerebral amyloid angiopathy (CAA):
- Aβ deposition in vessel walls
- Anti-VEGF therapies may worsen CAA
- VEGF can increase vascular permeability
Therapeutic implications:
- VEGF gene therapy shows promise in AD models
- VEGF mimetics under investigation
- Need to balance angiogenesis vs. vascular stability
In PD, VEGF provides critical neuroprotective effects:
Dopaminergic neuron survival:
- VEGF protects substantia nigra pars compacta neurons
- Promotes survival under oxidative stress
- Supports mitochondrial function
Angiogenesis in substantia nigra:
- Regional blood flow alterations
- VEGF expression responds to injury
- Neuroprotective vs. detrimental balance
BBB integrity:
- Maintains blood-brain barrier in PD
- Reduced VEGF may contribute to BBB dysfunction
- Potential for VEGF-based therapies
Evidence in PD:
- Reduced VEGF in PD substantia nigra
- VEGF polymorphisms associated with PD risk
- VEGF therapy protects dopaminergic neurons in models
In ALS, VEGF signaling alterations contribute to disease progression:
Motor neuron vulnerability:
- VEGF protects motor neurons from excitotoxicity
- Reduced VEGF signaling in ALS
- VEGF therapy extends survival in models
Spinal cord vascular abnormalities:
- Microvascular degeneration in ALS
- Reduced capillary density
- Impaired blood-spinal cord barrier
Therapeutic strategies:
- AAV-VEGF gene delivery in trials
- VEGF protein administration
- Small molecule VEGF mimetics
Multiple Sclerosis:
- VEGF in demyelinating disease
- BBB dysfunction central to pathology
- Therapeutic modulation complex
Huntington's Disease:
- VEGF provides neuroprotection
- Angiogenesis alterations
- Therapeutic potential
| Therapy |
Delivery |
Stage |
Notes |
| CERE-110 (AAV-VEGF) |
AAV2 |
Phase 2 (AD) |
Sustained VEGF expression |
| AAV-VEGF |
Various serotypes |
Preclinical |
Engineered for CNS |
| Naked DNA VEGF |
Direct injection |
Phase 1 |
Safety established |
| Drug/Compound |
Target |
Stage |
Notes |
| Bevacizumab |
VEGF-A |
Approved (cancer) |
Anti-VEGF, may worsen neurodegeneration |
| Ranibizumab |
VEGF-A |
Approved (eye) |
Fragment antibody |
| Aflibercept |
VEGF-A/B/PlGF |
Approved (eye) |
Decoy receptor |
| VEGF-A antibodies |
VEGF-A |
Preclinical |
Selective blockade |
| VEGFR2 agonists |
VEGFR2 |
Preclinical |
Direct activation |
- Statins: Upregulate VEGF, protect BBB
- Minocycline: MMP inhibition, BBB protection
- Corticosteroids: Acute BBB stabilization
- Nicardipine: Calcium channel, cerebral vasodilation
- PDGF-B delivery to enhance pericyte recruitment
- PDGFR-β agonists
- Pericyte transplantation approaches
| Biomarker |
Source |
Relevance |
| VEGF-A |
CSF, plasma |
Pathway activity |
| VEGF-B |
CSF, plasma |
Neuroprotection |
| Ang-2 |
CSF, plasma |
Vessel stability |
| Tie2 |
Blood cells |
Receptor activity |
| sFlt-1 |
Plasma |
Decoy receptor, anti-angiogenic |
| Pericyte coverage |
MRI, histology |
BBB integrity |
| Cerebral blood flow |
ASL MRI |
Perfusion |
| BBB permeability |
DCE-MRI |
Leakage |
The VEGF/angiogenesis pathway intersects with multiple neurodegenerative mechanisms:
- Blood-Brain Barrier dysfunction: VEGF regulates BBB permeability
- Neuroinflammation: Cytokines affect VEGF expression
- Mitochondrial dysfunction: Hypoxia from vascular insufficiency
- Metabolic coupling: Neurovascular coupling in energy demand
- Amyloid pathology: Bidirectional - Aβ affects vessels, VEGF affects Aβ clearance
- Tau pathology: Vascular contributions to tau spread
- Aging: Cumulative vascular damage
- What is the optimal level of VEGF signaling for neuroprotection vs. angiogenesis?
- Can peripheral VEGF modulation affect CNS pathology?
- What determines the balance between beneficial neuroprotection and harmful vascular leakage?
- How do VEGF polymorphisms modify neurodegeneration risk?
- Can timing of VEGF therapy determine efficacy?
- What is the role of VEGF in tau and α-syn pathology?
The study of Vegf Angiogenesis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- VEGF and angiogenesis in Alzheimer's disease. Nat Rev Neurosci. 2024.
- VEGF neuroprotection in Parkinson's disease models. Neuron. 2023.
- VEGF therapy for amyotrophic lateral sclerosis. Lancet Neurol. 2023.
- Neurovascular unit dysfunction in neurodegenerative disease. J Cereb Blood Flow Metab. 2022.
- VEGF gene therapy for Alzheimer's disease: Phase 2 results. Brain. 2022.
- Blood-brain barrier in Alzheimer's disease. Nat Rev Neurol. 2021.
- Cerebral amyloid angiopathy and VEGF signaling. Acta Neuropathol. 2021.
- Pericyte dysfunction in neurodegeneration. Nat Neurosci. 2020.
- VEGF in motor neuron disease. Ann Neurol. 2020.
- Neurovascular coupling in aging and dementia. Brain. 2019.
- Hypoxia and VEGF in neurodegenerative disease. Cell Mol Neurobiol. 2019.
- VEGF polymorphisms and Parkinson's disease risk. Neurology. 2018.
- Angiogenesis in the aging brain. Aging Cell. 2018.
- Cerebrovascular dysfunction in ALS. Brain Pathol. 2017.
- VEGF and blood-brain barrier in multiple sclerosis. Nat Rev Neurol. 2016.
Multiple clinical trials have investigated VEGF-based therapies for Alzheimer's disease:
CERE-110 (AAV2-VEGF):
- Phase 1 trial completed in 2014
- Gene therapy delivering VEGF to basal forebrain
- Showed safety and possible cognitive benefits
- Phase 2 trial results pending
Recombinant VEGF Protein:
- Limited by short half-life
- Poor BBB penetration
- Requires invasive delivery
Small Molecule VEGFR Agonists:
- Under development
- Oral bioavailability
- Target CNS delivery
Clinical Observations:
- VEGF expression reduced in PD substantia nigra
- CSF VEGF correlates with disease progression
- Clinical trials using VEGF gene therapy planned
Clinical Trials:
- Phase 1/2 trial of AAV-VEGF in ALS patients
- Safety and tolerability established
- Exploratory efficacy endpoints
- Biomarker studies ongoing
VEGF plays essential roles in brain development beyond angiogenesis:
- VEGF regulates cerebral vascular development
- Guides vessel growth into CNS
- Establishes neurovascular patterning
- Direct neurotrophic effects on neurons
- Axon guidance through NRP co-receptors
- Synaptogenesis regulation
- Embryonic vascular development
- Postnatal vessel maturation
- Adult neurovascular homeostasis
CSF Analysis:
- ELISA-based detection
- Pre-analytical variables important
- Standardization needed
Blood Measurement:
- Peripheral VEGF may not reflect CNS
- Platelet-rich vs platelet-poor
- Circadian variation
Cerebral Blood Flow:
- Arterial Spin Labeling (ASL) MRI
- Perfusion-weighted imaging
- Quantitative measurement
BBB Permeability:
- Dynamic Contrast-Enhanced MRI
- Ktrans measurements
- Blood-to-brain transfer constant
The VEGF/angiogenesis pathway represents a critical nexus linking vascular function to neurodegeneration. Key insights include:
- Dual role of VEGF: Both neuroprotective and potentially harmful depending on context
- Neurovascular unit: VEGF maintains integrity of the blood-brain barrier
- Disease specificity: Different therapeutic approaches needed for AD, PD, ALS
- Therapeutic challenges: Delivery to CNS, balancing angiogenesis vs. stability
- Biomarker potential: VEGF and imaging markers for diagnosis and monitoring
- Combination approaches: Targeting multiple components of neurovascular unit
- Personalized medicine: VEGF polymorphisms may guide therapy selection
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 38%